Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Core Points - Lipocine Inc. has entered into a license, development, and supply agreement with SPC Korea for exclusive rights to market TLANDO® in South Korea [1][2] - The agreement includes an upfront payment, regulatory and sales milestone payments, and royalties on net commercial sales for Lipocine [2] - SPC Korea will be responsible for obtaining regulatory approval in South Korea [2] Company Overview - Lipocine is a biopharmaceutical company focused on enhancing therapeutics through effective oral delivery using its proprietary technology platform [5] - TLANDO is a testosterone replacement therapy approved by the US FDA for adult males with conditions related to endogenous testosterone deficiency [4][6] - The company is developing various drug candidates targeting significant unmet medical needs, including treatments for postpartum depression, epilepsy, essential tremor, chronic weight management, and liver cirrhosis [6]